Dublin-based Amarin Pharma files patent case against Dr Reddys Laboratories

Press Trust of India | Updated On: May 04, 2014 14:48 (IST)

').appendTo($('#gta_top')); $('').appendTo($('#gta_top')); },3000); /* s += ''; s += ''; */ } else if (google_ads.length > 1) { s += ''; } s += '

' } } // document.write(s); return; } // --> google_ad_client = "pub-7641565019577886"; /* 468x60, created 3/6/09 */ google_ad_slot = "8438645248"; google_ad_width = 620; google_ad_height = 70; google_max_num_ads = 1; google_ad_type = 'text'; google_ad_output = 'js'; //-->

Hyderabad: Dublin-based Amarin Pharma has filed a patent infringement case against Dr. Reddy's Laboratories Ltd (DRL) alleging that the Hyderabad-based pharma company is attempting to come out with generic versions of its patented drug Vascepa.
 
Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (=500 mg/dL) hypertriglyceridemia.
 
Amarin alleged that the Indian drug maker's abbreviated new drug application (ANDA), seeking to market the generic version, would infringe the patent of Vascepa on 16 counts.
 
"A permanent injunction restraining and enjoining DRL and its officers, agents, servants, employees, parents, subsidiaries, divisions, affiliates, and those persons in active concert or participation with any of them, from making, using, selling, offering to sell, or importing any product that infringes the...patents, including the product described in ANDA No. 205616," Amarin requested the court.
 
According to a pharma industry expert, the lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of the ANDA by Dr. Reddy's until the expiry of the patents or final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivity.
 
"Patent infringement cases are not uncommon for generic drug makers in the USA. The lawsuit will not have any implications on the performance of the company," said a senior official of a city-based pharmaceutical company.
 
Most of the patents of Vascepa would expire in 2030, according to reports. 

RESULT

Patent Docs: Court Report
Biotech & Pharma Patent Law Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.; Dr. Reddy's Laboratories, Amarin Pharmaceuticals Ireland Ltd. v. Omthera

Patent Docs: March 2014
Biotech & Pharma Patent Law Cephalon Inc. v. Dr. Reddy's Laboratories Ltd based on the merits of the case, the large majority went against the

Olivistar v. Netgear
files this Complaint against This Court has subject matter jurisdiction over this case for patent Amarin Pharma et. al. v. Dr. Reddy's Laboratories

Parallel Separation Innovations v. Schlumberger N.V. et. al.
Official Complaint for Patent Infringement in Separation Innovations LLC files this Complaint against Defendants Pharma et. al. v. Dr. Reddy's Laboratories et

IPR & Regulatory Centre
Pfizers Sutent Patent Case Against Cipla Indian Pharma Companies Like Ranbaxy, Dr Reddys & Others eye $1bn Bayer Files Patent on Manufacturing

Generics News Archives for Drug Development
complaint against Mylan Pharmaceuticals has cost files patent infringement suit against against Dr. Reddy's Laboratories alleging that the

BioSpace offers Pharmaceutical, Biotechnology and ...
No Criminal Case Against Ranbaxy Laboratories Cancer Drug Patent in Latest Big Pharma Blow 8/2 Sues Dr. Reddy's Laboratories Ltd. for Patent

:: VSERVE pharma ::
India set to rule in Novartis patent case FiercePharma : Synergy Pharmaceuticals Files IND for SP Dr. Reddy's Laboratories Increases Sales but Misses

Healthcare Sales & Marketing Network News: ICOS
Patent Case in Delaware District Court # Valeant Pharmaceuticals # Dr. Reddy's Laboratories # Cloderm # clocortolone. # Amarin Corp # MARINE study # AMR101.

Biologics Process Development - Contract Pharma
Search Contract Pharma . Try: biomanufacturing, FDA. Subscribe Free Magazine eNewsletter. Magazine. Current Issue; Issue Case Study; White Papers;